Kolexia
Philibert Patrick Médecine générale
Philibert Patrick
Médecine générale
Cabinet libéral
Marseille, France
67 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Infections à VIH Maladies sexuellement transmissibles Maladies transmissibles émergentes Maladies transmissibles Hépatite Hépatite B COVID-19 Hépatite C Maladies du foie

Collaborateurs

Voir plus
Halfon Philippe
Halfon Philippe
Cabinet libéral, Marseille, France
Enel Patricia
Enel Patricia
Hôpital La Conception, Marseille, France
Chiche Laurent
Chiche Laurent
Cabinet libéral, Marseille, France
Retornaz Frederique
Retornaz Frederique
Cabinet libéral, Marseille, France

Industries

Voir plus
ViiV Healthcare
28 collaboration(s)
Dernière en 2023
Gilead
15 collaboration(s)
Dernière en 2023
MSD
9 collaboration(s)
Dernière en 2023
Eusa Pharma
1 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants: A Phase III, Randomized, Multicenter, Parallel-group, Open-Label Study Evaluating the Efficacy, Safety, and Tolerability of Long-Acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor Single Tablet Regimen in HIV-1 Infected Antiretroviral Therapy Naive Adult Participants
Essai Clinique (ViiV Healthcare)   14 février 2024
Clinical and pharmacological outcomes of real-world use of Long-Acting Cabotegravir and Rilpivirine in France: Efficacy and tolerance during the first 72 weeks
HIV medicine Congress 2023   01 décembre 2023
CARAVEL: Evaluation of real-world antiviral effectiveness and sustainability of the 2-drug regimen Dolutegravir/Lamivudine fixed dose combination (FDC) in treatment-naïve adults and pre-treated adults who are virologicaly suppressed, in routine clinical care, in France. One-year interim analysis results
HIV medicine Congress 2023   01 décembre 2023
Traitement préventif contre le VIH : "Certains médecins ne se sentent ...
France 2 Régions   01 décembre 2023
DOMINO: A Phase IIb, Randomized, Partially Blind, Active Controlled, Dose-range Finding Study of GSK3640254 Compared to a Reference Arm of Dolutegravir, Each in Combination With Nucleoside Reverse Transcriptase Inhibitors, in HIV-1 Infected Antiretroviral Treatment-naive Adults
Essai Clinique (ViiV Healthcare)   26 octobre 2023
MAGICIEN: Prospective Clinical Performance Evaluation of the In-Vitro Diagnostics Medical Device MaGIA IBC for the CombIned screENing of HIV, Hepatitis B and Hepatitis C
Essai Clinique (MagIA Diagnostics)   09 octobre 2023
Anti-spike protein to determine SARS-CoV-2 antibody levels: Is there a specific threshold conferring protection in immunocompromised patients?
PloS one   28 avril 2023
Phase IIa Proof-of-Concept Evaluation of the Antiviral Efficacy, Safety, Tolerability, and Pharmacokinetics of the Next-Generation Maturation Inhibitor GSK3640254.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America   19 septembre 2022
A cohort analysis of sexually transmitted infections among different groups of men who have sex with men in the early era of HIV pre-exposure prophylaxis in France.
Journal of virus eradication   24 février 2022
An optimized stepwise algorithm combining rapid antigen and RT-qPCR for screening of COVID-19 patients.
PloS one   23 septembre 2021